Translational Medicine
Open Access

Department of Stem Cell Therapy, Nutech Mediworld, India

Publications

• Short Communication   
  Translational Medicine 2015: Authorizing the efficiency of the Human Embryonic Stem Cell (hESC) therapy in cerebral palsy patients - Geeta Shroff - Nutech Mediworld
  Author(s): Geeta Shroff*
  
  Background: The present study evaluated the efficacy and safety of human embryonic somatic cell (hESC) therapy in patients with Cerebral Palsy (CP). Methods: This analysis comprised patients (30 days-18 years) with predictable identification of CP. The study consisted of four treatment phases (T1, T2, T3, T4) separated by gap phases. Efficacy of hESC therapy was evaluated supported Gross Motor Function Classification Scores Expanded and Revised (GMFCS-E & R; 1-good to 5-bad). Results: Ninety one patients were included and every one received hESC therapy in T1, 66 patients returned for T2, 38 patients for T3, and 15 patients for T4. General, 31.2% patients attained GMFCS-E & R score 1 throughout the study with dissimilar number of patients attaining GMFCS score 1 by the top of every single treatment phase (T1: 6 [6.6%]; T2: 7 [10.6%]; T3: 11 [28.9%]; and T4:.. View More»
  DOI: 10.35248/2161-1025.20.10.205

  Abstract HTML PDF